Eledon Pharmaceuticals (ELDN) Research & Development (2013 - 2026)

Eledon Pharmaceuticals has reported Research & Development for 14 years, with the latest figure at $17.2 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 27.09% year-over-year to $17.2 million; the trailing twelve-month figure through Mar 2026 stood at $66.0 million (up 13.58% YoY), and the FY2024 full-year result was $52.0 million, up 71.43% from the prior year.
• Research & Development for Q1 2026 stood at $17.2 million, up from $15.0 million in the prior quarter.
• The five-year high for Research & Development was $20.3 million in Q2 2025, with the low at $5.7 million in Q2 2022.
• Historically, Research & Development has averaged $11.0 million across 5 years, with a median of $8.0 million in 2023.
• Annual changes were most pronounced in 2024 — Research & Development surged 153.69% — and 2025, when it decreased 9.39%.
• Eledon Pharmaceuticals' Research & Development stood at $7.2 million in 2022, then declined by 2.52% to $7.1 million in 2023, then surged by 153.69% to $17.9 million in 2024, then retreated by 16.5% to $15.0 million in 2025, then advanced by 14.88% to $17.2 million in 2026.
• The last three Research & Development figures came in at $17.2 million (Q1 2026), $15.0 million (Q3 2025), and $20.3 million (Q2 2025), per Business Quant data.